Slevin M - Search Results

1

Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.

Joel SP, Ellis P, O'Byrne K, Papamichael D, Hall M, Penson R, Nicholls S, O'Donnell C, Constantinou A, Woodhull J, Nicholson M, Smith I, Talbot D, Slevin M. Joel SP, et al. Among authors: slevin m. J Clin Oncol. 1996 Jun;14(6):1903-12. doi: 10.1200/JCO.1996.14.6.1903. J Clin Oncol. 1996. PMID: 8656259 Clinical Trial.

2

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy.

Mainwaring PN, Nicolson MC, Hickish T, Penson R, Joel S, Slevin M, Smith IE. Mainwaring PN, et al. Among authors: slevin m. Br J Cancer. 1997;76(12):1636-9. doi: 10.1038/bjc.1997.609. Br J Cancer. 1997. PMID: 9413954 Free PMC article. Clinical Trial.

3

Effects of haemopoietic growth factors in combination with etoposide on sister chromatid exchange frequencies in peripheral blood mononuclear cells.

Liu WM, Bamford C, Slevin M, Joel SP. Liu WM, et al. Among authors: slevin m. Cancer Chemother Pharmacol. 1998;41(4):343-6. doi: 10.1007/s002800050749. Cancer Chemother Pharmacol. 1998. PMID: 9488605

4

A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer.

Joel S, O'Byrne K, Penson R, Papamichael D, Higgins A, Robertshaw H, Rudd R, Talbot D, Slevin M. Joel S, et al. Among authors: slevin m. Ann Oncol. 1998 Nov;9(11):1205-11. doi: 10.1023/a:1008437805286. Ann Oncol. 1998. PMID: 9862051 Free article. Clinical Trial.

5

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PF. Slevin ML, et al. J Clin Oncol. 1989 Sep;7(9):1333-40. doi: 10.1200/JCO.1989.7.9.1333. J Clin Oncol. 1989. PMID: 2549204 Clinical Trial.

6

Stability of the i.v. and oral formulations of etoposide in solution.

Joel SP, Clark PI, Slevin ML. Joel SP, et al. Among authors: slevin ml. Cancer Chemother Pharmacol. 1995;37(1-2):117-24. doi: 10.1007/BF00685638. Cancer Chemother Pharmacol. 1995. PMID: 7497580

7

A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.

Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PW, Reznek R, Masud T, Gregory W, Wrigley PF. Clark PI, et al. Among authors: slevin ml. J Clin Oncol. 1994 Jul;12(7):1427-35. doi: 10.1200/JCO.1994.12.7.1427. J Clin Oncol. 1994. PMID: 8021734 Clinical Trial.

8

Etoposide dosage and pharmacodynamics.

Joel SP, Shah R, Slevin ML. Joel SP, et al. Among authors: slevin ml. Cancer Chemother Pharmacol. 1994;34 Suppl:S69-75. doi: 10.1007/BF00684867. Cancer Chemother Pharmacol. 1994. PMID: 8070031 Review.

9

Schedule-dependent topoisomerase II-inhibiting drugs.

Joel SP, Slevin ML. Joel SP, et al. Among authors: slevin ml. Cancer Chemother Pharmacol. 1994;34 Suppl:S84-8. doi: 10.1007/BF00684869. Cancer Chemother Pharmacol. 1994. PMID: 8070033 Review.

10

Prolonged oral etoposide in small cell lung cancer.

Slevin ML, Joel SP. Slevin ML, et al. Ann Oncol. 1993 Aug;4(7):529-32. doi: 10.1093/oxfordjournals.annonc.a058583. Ann Oncol. 1993. PMID: 8395869 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

417 results

Search Page

Filters